Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 12, 2022
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
[ Thu, May 12th 2022
] - WOPRAI
Nathan Rich Maintained (TEVA) at Hold with Decreased Target to $9 on, May 12th, 2022
Nathan Rich of Goldman Sachs, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Decreased Target from $10 to $9 on, May 12th, 2022.
Nathan has made no other calls on TEVA in the last 4 months.
There are 3 other peers that have a rating on TEVA. Out of the 3 peers that are also analyzing TEVA, 1 agrees with Nathan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, January 27th, 2022
These are the ratings of the 2 analyists that currently disagree with Nathan
- David Amsellem of "Piper Sandler" Downgraded from Hold to Sell and Decreased Target to $7 on, Wednesday, May 4th, 2022
- Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
